Dr. Annalisa Jenkins

Chief Executive Officer of Dimension Therapeutics

Dr. Annalisa Jenkins, MBBS, FRCP is the chief executive officer of Dimension.  A biopharma thought leader with nearly 20 years of industry experience, Dr. Jenkins has built and led teams advancing programs from scientific research through clinical development, regulatory approval and into healthcare systems globally. 

Prior to joining Dimension, Dr. Jenkins served as executive vice president, head of Global Research and Development for Merck Serono. She also led Global Medical Affairs and Quality and was a member of Merck Serono’s Pharmaceutical Executive Committee. Previously, Dr. Jenkins pursued a nearly 15-year career at Bristol-Myers Squibb (BMS), attaining the role of senior vice president and head of Global Medical Affairs. She began her career as a medical officer with the British Royal Navy during the Gulf conflict, rising to the rank of Surgeon Lieutenant Commander. Dr. Jenkins graduated in medicine from St. Bartholomew’s Hospital London and trained in cardiovascular medicine in the UK National Health Service.

Dr. Jenkins is a member of the Board of Directors of Ardelyx, Biothera, MedCity, and Viventia Bio, Inc. She also is a member of the European Commission’s Scientific Panel for Health, a science-led expert group tasked with helping to achieve better health and wellbeing for all. In addition, Dr. Jenkins is a committee member of the Science Board to the U.S. Food & Drug Administration, which advises FDA leadership on complex scientific and technical issues.